Biogen
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its establish...
Latest News
7 hours ago · prnewswire.com
New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026Benefits of continuous lecanemab treatment in early Alzheimer's disease accrue over time Lecanemab reduced the relative risk of progression to the next stage of disease by 36% vs. ADNI 62% of patients with low tau showed improvement in cognitive function and activities of daily living (CDR-SB) at five years TOKYO and CAMBRIDGE, Mass.
20 hours ago · businesswire.com
TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative DiseaseCAMBRIDGE, England--(BUSINESS WIRE)--TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has entered into a strategic research collaboration, option, and license agreement with Biogen International GmbH. Under the terms of the agreement, Biogen and TRIMTECH will work collaboratively to discover and develop small molecule protein degraders for the treatme.
4 days ago · globenewswire.com
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer's DiseaseThe First and Only Anti-Amyloid Treatment in Japan that Enables At-Home Administration The First and Only Anti-Amyloid Treatment in Japan that Enables At-Home Administration
6 days ago · 247wallst.com
Two Neighbors Will Start Leqembi, Listed at $28,270 a Year. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% of Medicare-Approved Infusion CostsTwo neighbors get the same Alzheimer's diagnosis and the same prescription, yet only one can count on a manageable bill. A missed registry rule and a closed enrollment window could decide who pays, and the clock runs out December 7.
19 days ago · benzinga.com
These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 ResultsBiogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter.
19 days ago · globenewswire.com
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab presentations will highlight new long-term and real-world evidence, including initial five-year Clarity AD open-label extension data and three-year LEADER data, with new analyses exploring maintenance treatment and at-home subcutaneous administration Presentations across Biogen's Alzheimer's disease portfolio reflect its continued commitment to advancing innovation in Alzheimer's disease, from long-term treatment outcomes and real-world evidence to investigational approaches targeting core disease pathologies, including amyloid and tau CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer's disease portfolio at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place November 16–19, 2026, at the Boston Marriott Copley Place in Boston, Massachusetts.
19 days ago · marketbeat.com
Biogen Q3 Earnings Call HighlightsBiogen NASDAQ: BIIB reported third-quarter 2026 revenue growth of 11% year over year, supported by its acquisition of Apellis and continued expansion of its growth-product portfolio. Management said the company remains on track to return to top-line growth in 2026 and raised the lower end of its full-year non-GAAP diluted earnings-per-share guidance.
19 days ago · seekingalpha.com
Biogen Inc. (BIIB) Q3 2026 Earnings Call TranscriptBiogen Inc. ( BIIB ) Q3 2026 Earnings Call October 28, 2026 8:30 AM EDT Company Participants Tim Power - Head of Investor Relations Christopher Viehbacher - President, CEO & Director Priya Singhal - Executive VP & Head of Development Robin Kramer - Executive VP & CFO Alisha Alaimo - President & Head of North America Conference Call Participants Philip Nadeau - TD Cowen, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Brian Abrahams - RBC Capital Markets, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Michael Yee - UBS Investment Bank, Research Division Alexandria Hammond - Wolfe Research, LLC Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Evan Seigerman - BMO Capital Markets Equity Research Geoffrey Meacham - Citigroup Inc., Research Division David Amsellem - Piper Sandler & Co., Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Lin Tsai - Jefferies LLC, Research Division Marc Goodman - Leerink Partners LLC, Research Division Presentation Operator Good morning. My name is Cynthia, and I will be your conference operator today.
19 days ago · zacks.com
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View TightenedBiogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.
20 days ago · zacks.com
Big Day for Econ Data, Hyperscaler EarningsWe have a solid slate of reports today, both of the earnings variety and regarding economic growth.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove BIIB